Global Molecular Biology Experimental Instruments Market Growth (Status and Outlook) 2025-2031

The global Molecular Biology Experimental Instruments market size is predicted to grow from US$ 630 million in 2025 to US$ 869 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.

Rapid extraction of viral DNA or RNA from plasma, serum, urine, ascites, cell culture fluid, supernatant, cell-free body fluid, can be used in various common downstream experiments, such as restriction digestion, reverse transcription, etc.

The global medical device market is estimated to be US$603.3 billion in 2023, with a compound annual growth rate of 5% expected in the next six years. Global health care expenditure currently accounts for approximately 10% of global GDP, and the proportion will continue to increase in the next few years. This is primarily due to the increasing demand for healthcare from an aging population, the rising prevalence of chronic and infectious diseases, and the expansion of emerging markets. The medical device market plays an important role in the healthcare spending industry. The medical device market is driven by a variety of factors, including increasing global demand for advanced medical services, advancements in medical technology, growing geriatric population, increasing medical expenditures, and increasing awareness of early stage disease diagnosis and treatment.

LPI (LP Information)' newest research report, the “Molecular Biology Experimental Instruments Industry Forecast” looks at past sales and reviews total world Molecular Biology Experimental Instruments sales in 2024, providing a comprehensive analysis by region and market sector of projected Molecular Biology Experimental Instruments sales for 2025 through 2031. With Molecular Biology Experimental Instruments sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Biology Experimental Instruments industry.

This Insight Report provides a comprehensive analysis of the global Molecular Biology Experimental Instruments landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Molecular Biology Experimental Instruments portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Biology Experimental Instruments market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Biology Experimental Instruments and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Biology Experimental Instruments.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Biology Experimental Instruments market by product type, application, key players and key regions and countries.

Segmentation by Type:
Infectious Disease
Respiratory Disease
For Cancer
Gene Mutation
Gastrointestinal Disease
Others

Segmentation by Application:
Hospital
Clinic
Research Center
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Seegene
SPACEGEN
VITASSAY HEALTHCARE S.L.
Yaneng Bioscience (Shenzhen) Co., Ltd.
Zhejiang Orient Gene
ELITech Group
Fujirebio
Jiangsu Bioperfectus Technologies Co., Ltd.
Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
Altona Diagnostics GmbH
NZYTech
ATTOPLEX
OSANG Healthcare
Panagene Inc.
PCRmax
R-Biopharm AG
AB Analitica
Celnovte Biotechnology Co., Ltd.
Elisabeth Pharmacon Spol
Jiangsu Mole Bioscience CO., LTD.
Medical Innovation Ventures
Randox Laboratories

Please note: The report will take approximately 2 business days to prepare and deliver. Show more